Our study not only provides insight into the molecular mechanism of MEK inhibitor resistance but also suggests a novel combination therapy of STAT3 and MEK inhibitors could be a potential therapeutic strategy for preventing and/or overcoming resistance of MEK inhibitor in patients with colorectal and pancreatic cancers. This evidence concerns the gene STAT3 and familial pancreatic carcinoma.